Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net Revenue	$ 21,671,599	$ 16,024,948	$ 60,367,060	$ 47,300,029
Cost of goods sold	1,991,987	1,751,349	5,890,719	6,064,524
Gross profit	19,679,612	14,273,599	54,476,341	41,235,505
Operating expenses
Selling, general and administrative expenses	18,993,255	13,877,879	54,143,122	40,658,424
Research and development	1,359,530	986,454	3,291,479	3,480,906
Depreciation and amortization	1,103,854	997,674	3,314,781	2,580,243
Change in fair value of earnout liabilities	147,000	(681,753)	67,549	(1,494,910)
Total operating expenses	21,603,639	15,180,254	60,816,931	45,224,663
Operating loss	(1,924,027)	(906,655)	(6,340,590)	(3,989,158)
Other expense
Interest expense	(927,577)	(188,294)	(1,839,259)	(188,300)
Share of losses from equity method investment	(31,448)		(31,448)
Total other expense	(959,025)	(188,294)	(1,870,707)	(188,300)
Net loss	(2,883,052)	(1,094,949)	(8,211,297)	(4,177,458)
Less: Net loss attributable to noncontrolling interest	(25,284)	(34,579)	(85,331)	(111,455)
Net loss attributable to Sanara MedTech shareholders	$ (2,857,768)	$ (1,060,370)	$ (8,125,966)	$ (4,066,003)
Net loss per share of common stock, basic	$ (0.34)	$ (0.13)	$ (0.96)	$ (0.49)
Net loss per share of common stock, diluted	$ (0.34)	$ (0.13)	$ (0.96)	$ (0.49)
Weighted average number of common shares outstanding, basic	8,517,381	8,332,341	8,468,394	8,244,503
Weighted average number of common shares outstanding, diluted	8,517,381	8,332,341	8,468,394	8,244,503